Loading…

Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques

Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this st...

Full description

Saved in:
Bibliographic Details
Published in:Molecular therapy. Methods & clinical development 2016-01, Vol.3 (C), p.16079-16079, Article 16079
Main Authors: Greig, Jenny A, Nordin, Jayme Ml, Bote, Erin, Makaron, Leah, Garnett, Mason E, Kattenhorn, Lisa M, Bell, Peter, Goode, Tamara, Wilson, James M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3
cites cdi_FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3
container_end_page 16079
container_issue C
container_start_page 16079
container_title Molecular therapy. Methods & clinical development
container_volume 3
creator Greig, Jenny A
Nordin, Jayme Ml
Bote, Erin
Makaron, Leah
Garnett, Mason E
Kattenhorn, Lisa M
Bell, Peter
Goode, Tamara
Wilson, James M
description Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this study, we evaluated the impact of intravenous infusion rate of AAV8 vector in cynomolgus macaques on transgene expression, vector clearance from the circulation, and potential activation of the innate immune system. The dose of AAV8 vector in terms of genome copies per kilogram body weight and its concentration were fixed, while the rate of infusion varied to deliver the entire dose over different time periods, including 1, 10, or 90 minutes. Analyses during the in-life phase of the experiment included sequential evaluation of whole blood for vector genomes and appearance of proinflammatory cytokines. Liver tissues were analyzed at the time of necropsy for enhanced green fluorescent protein (eGFP) expression and vector genomes. The data were remarkable with a relative absence of any statistically significant effect of infusion time on vector transduction, safety, and clearance. However, some interesting and unexpected trends did emerge.
doi_str_mv 10.1038/mtm.2016.79
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1257334449464218b79428fe5b2e4286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1257334449464218b79428fe5b2e4286</doaj_id><sourcerecordid>2307590046</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3</originalsourceid><addsrcrecordid>eNp9ks1rFDEYxoMotqw9eZeAF8Hums9J5iIsxdaFghf1GjKZZJt1JlmTzML615txa2k9mMv7kjz5kffJA8BrjFYYUflhLOOKINysRPsMnBNK2iXiCD9_1J-Bi5x3qK5WIMrbl-CMiJZSisQ5-LUZ99oUGB30oSR9sCFOufZuyj4GWPxoYa3r9XcJD9aUmOD-TqdRm_jDB1u8yZcwa2fL8RLq0MPBH2yCFRVyP5kyQ3yA5hjiGIdtZder-udk8yvwwukh24v7ugDfrj99vfq8vP1ys7la3y4NR7QsuetZa_pec0Z6S5lrSCOcQVwywyiXpkHUaNGx1lpCDMaGOYGRM4R2BFlHF2Bz4vZR79Q--VGno4raqz8bMW2VTnWOwSpMuKCUMdayhhEsO9EyIp3lHbG1aSrr44m1n7rR9sbOng1PoE9Pgr9T23hQHDPCkayAd_eAFGcTihp9NnYYdLDVeIUlE7J-jqRV-vYf6S5OKVSrFKl_x1uEWPM_VWU1jAqBSVW9P6lMijkn6x6ejJGag6RqkNQcJFWjsQBvHk_5oP0bG_obYGbDsQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1846437712</pqid></control><display><type>article</type><title>Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><source>ScienceDirect Journals</source><creator>Greig, Jenny A ; Nordin, Jayme Ml ; Bote, Erin ; Makaron, Leah ; Garnett, Mason E ; Kattenhorn, Lisa M ; Bell, Peter ; Goode, Tamara ; Wilson, James M</creator><creatorcontrib>Greig, Jenny A ; Nordin, Jayme Ml ; Bote, Erin ; Makaron, Leah ; Garnett, Mason E ; Kattenhorn, Lisa M ; Bell, Peter ; Goode, Tamara ; Wilson, James M</creatorcontrib><description>Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this study, we evaluated the impact of intravenous infusion rate of AAV8 vector in cynomolgus macaques on transgene expression, vector clearance from the circulation, and potential activation of the innate immune system. The dose of AAV8 vector in terms of genome copies per kilogram body weight and its concentration were fixed, while the rate of infusion varied to deliver the entire dose over different time periods, including 1, 10, or 90 minutes. Analyses during the in-life phase of the experiment included sequential evaluation of whole blood for vector genomes and appearance of proinflammatory cytokines. Liver tissues were analyzed at the time of necropsy for enhanced green fluorescent protein (eGFP) expression and vector genomes. The data were remarkable with a relative absence of any statistically significant effect of infusion time on vector transduction, safety, and clearance. However, some interesting and unexpected trends did emerge.</description><identifier>ISSN: 2329-0501</identifier><identifier>EISSN: 2329-0501</identifier><identifier>DOI: 10.1038/mtm.2016.79</identifier><identifier>PMID: 27933307</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Animals ; Body weight ; Clinical trials ; Cytokines ; Cytotoxicity ; Deoxyribonucleic acid ; DNA ; Efficiency ; Enzymes ; Gene therapy ; Genomes ; Green fluorescent protein ; Immune clearance ; Immune system ; Immunology ; Inflammation ; Innate immunity ; Intravenous administration ; Liver ; Necropsy ; Pharmacokinetics ; Statistical analysis ; Vectors (Biology) ; Veins &amp; arteries</subject><ispartof>Molecular therapy. Methods &amp; clinical development, 2016-01, Vol.3 (C), p.16079-16079, Article 16079</ispartof><rights>Copyright Nature Publishing Group Dec 2016</rights><rights>2016. Official journal of the American Society of Gene &amp; Cell Therapy</rights><rights>Copyright © 2016 Official journal of the American Society of Gene &amp; Cell Therapy 2016 Official journal of the American Society of Gene &amp; Cell Therapy</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3</citedby><cites>FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142508/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2307590046?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27933307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Greig, Jenny A</creatorcontrib><creatorcontrib>Nordin, Jayme Ml</creatorcontrib><creatorcontrib>Bote, Erin</creatorcontrib><creatorcontrib>Makaron, Leah</creatorcontrib><creatorcontrib>Garnett, Mason E</creatorcontrib><creatorcontrib>Kattenhorn, Lisa M</creatorcontrib><creatorcontrib>Bell, Peter</creatorcontrib><creatorcontrib>Goode, Tamara</creatorcontrib><creatorcontrib>Wilson, James M</creatorcontrib><title>Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques</title><title>Molecular therapy. Methods &amp; clinical development</title><addtitle>Mol Ther Methods Clin Dev</addtitle><description>Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this study, we evaluated the impact of intravenous infusion rate of AAV8 vector in cynomolgus macaques on transgene expression, vector clearance from the circulation, and potential activation of the innate immune system. The dose of AAV8 vector in terms of genome copies per kilogram body weight and its concentration were fixed, while the rate of infusion varied to deliver the entire dose over different time periods, including 1, 10, or 90 minutes. Analyses during the in-life phase of the experiment included sequential evaluation of whole blood for vector genomes and appearance of proinflammatory cytokines. Liver tissues were analyzed at the time of necropsy for enhanced green fluorescent protein (eGFP) expression and vector genomes. The data were remarkable with a relative absence of any statistically significant effect of infusion time on vector transduction, safety, and clearance. However, some interesting and unexpected trends did emerge.</description><subject>Animals</subject><subject>Body weight</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Efficiency</subject><subject>Enzymes</subject><subject>Gene therapy</subject><subject>Genomes</subject><subject>Green fluorescent protein</subject><subject>Immune clearance</subject><subject>Immune system</subject><subject>Immunology</subject><subject>Inflammation</subject><subject>Innate immunity</subject><subject>Intravenous administration</subject><subject>Liver</subject><subject>Necropsy</subject><subject>Pharmacokinetics</subject><subject>Statistical analysis</subject><subject>Vectors (Biology)</subject><subject>Veins &amp; arteries</subject><issn>2329-0501</issn><issn>2329-0501</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ks1rFDEYxoMotqw9eZeAF8Hums9J5iIsxdaFghf1GjKZZJt1JlmTzML615txa2k9mMv7kjz5kffJA8BrjFYYUflhLOOKINysRPsMnBNK2iXiCD9_1J-Bi5x3qK5WIMrbl-CMiJZSisQ5-LUZ99oUGB30oSR9sCFOufZuyj4GWPxoYa3r9XcJD9aUmOD-TqdRm_jDB1u8yZcwa2fL8RLq0MPBH2yCFRVyP5kyQ3yA5hjiGIdtZder-udk8yvwwukh24v7ugDfrj99vfq8vP1ys7la3y4NR7QsuetZa_pec0Z6S5lrSCOcQVwywyiXpkHUaNGx1lpCDMaGOYGRM4R2BFlHF2Bz4vZR79Q--VGno4raqz8bMW2VTnWOwSpMuKCUMdayhhEsO9EyIp3lHbG1aSrr44m1n7rR9sbOng1PoE9Pgr9T23hQHDPCkayAd_eAFGcTihp9NnYYdLDVeIUlE7J-jqRV-vYf6S5OKVSrFKl_x1uEWPM_VWU1jAqBSVW9P6lMijkn6x6ejJGag6RqkNQcJFWjsQBvHk_5oP0bG_obYGbDsQ</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Greig, Jenny A</creator><creator>Nordin, Jayme Ml</creator><creator>Bote, Erin</creator><creator>Makaron, Leah</creator><creator>Garnett, Mason E</creator><creator>Kattenhorn, Lisa M</creator><creator>Bell, Peter</creator><creator>Goode, Tamara</creator><creator>Wilson, James M</creator><general>Elsevier Limited</general><general>Nature Publishing Group</general><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20160101</creationdate><title>Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques</title><author>Greig, Jenny A ; Nordin, Jayme Ml ; Bote, Erin ; Makaron, Leah ; Garnett, Mason E ; Kattenhorn, Lisa M ; Bell, Peter ; Goode, Tamara ; Wilson, James M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Body weight</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Efficiency</topic><topic>Enzymes</topic><topic>Gene therapy</topic><topic>Genomes</topic><topic>Green fluorescent protein</topic><topic>Immune clearance</topic><topic>Immune system</topic><topic>Immunology</topic><topic>Inflammation</topic><topic>Innate immunity</topic><topic>Intravenous administration</topic><topic>Liver</topic><topic>Necropsy</topic><topic>Pharmacokinetics</topic><topic>Statistical analysis</topic><topic>Vectors (Biology)</topic><topic>Veins &amp; arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Greig, Jenny A</creatorcontrib><creatorcontrib>Nordin, Jayme Ml</creatorcontrib><creatorcontrib>Bote, Erin</creatorcontrib><creatorcontrib>Makaron, Leah</creatorcontrib><creatorcontrib>Garnett, Mason E</creatorcontrib><creatorcontrib>Kattenhorn, Lisa M</creatorcontrib><creatorcontrib>Bell, Peter</creatorcontrib><creatorcontrib>Goode, Tamara</creatorcontrib><creatorcontrib>Wilson, James M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Molecular therapy. Methods &amp; clinical development</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Greig, Jenny A</au><au>Nordin, Jayme Ml</au><au>Bote, Erin</au><au>Makaron, Leah</au><au>Garnett, Mason E</au><au>Kattenhorn, Lisa M</au><au>Bell, Peter</au><au>Goode, Tamara</au><au>Wilson, James M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques</atitle><jtitle>Molecular therapy. Methods &amp; clinical development</jtitle><addtitle>Mol Ther Methods Clin Dev</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>3</volume><issue>C</issue><spage>16079</spage><epage>16079</epage><pages>16079-16079</pages><artnum>16079</artnum><issn>2329-0501</issn><eissn>2329-0501</eissn><abstract>Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this study, we evaluated the impact of intravenous infusion rate of AAV8 vector in cynomolgus macaques on transgene expression, vector clearance from the circulation, and potential activation of the innate immune system. The dose of AAV8 vector in terms of genome copies per kilogram body weight and its concentration were fixed, while the rate of infusion varied to deliver the entire dose over different time periods, including 1, 10, or 90 minutes. Analyses during the in-life phase of the experiment included sequential evaluation of whole blood for vector genomes and appearance of proinflammatory cytokines. Liver tissues were analyzed at the time of necropsy for enhanced green fluorescent protein (eGFP) expression and vector genomes. The data were remarkable with a relative absence of any statistically significant effect of infusion time on vector transduction, safety, and clearance. However, some interesting and unexpected trends did emerge.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>27933307</pmid><doi>10.1038/mtm.2016.79</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2329-0501
ispartof Molecular therapy. Methods & clinical development, 2016-01, Vol.3 (C), p.16079-16079, Article 16079
issn 2329-0501
2329-0501
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_1257334449464218b79428fe5b2e4286
source PubMed (Medline); Publicly Available Content Database; ScienceDirect Journals
subjects Animals
Body weight
Clinical trials
Cytokines
Cytotoxicity
Deoxyribonucleic acid
DNA
Efficiency
Enzymes
Gene therapy
Genomes
Green fluorescent protein
Immune clearance
Immune system
Immunology
Inflammation
Innate immunity
Intravenous administration
Liver
Necropsy
Pharmacokinetics
Statistical analysis
Vectors (Biology)
Veins & arteries
title Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A46%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20intravenous%20infusion%20time%20on%20AAV8%20vector%20pharmacokinetics,%20safety,%20and%20liver%20transduction%20in%20cynomolgus%20macaques&rft.jtitle=Molecular%20therapy.%20Methods%20&%20clinical%20development&rft.au=Greig,%20Jenny%20A&rft.date=2016-01-01&rft.volume=3&rft.issue=C&rft.spage=16079&rft.epage=16079&rft.pages=16079-16079&rft.artnum=16079&rft.issn=2329-0501&rft.eissn=2329-0501&rft_id=info:doi/10.1038/mtm.2016.79&rft_dat=%3Cproquest_doaj_%3E2307590046%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c503t-5fd49cdda542de34f6267fc0584c4358c603ca7b49ee22c11c4f710fc23b20ef3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1846437712&rft_id=info:pmid/27933307&rfr_iscdi=true